Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience

References

1. ↵
   Suh DC, Kim SJ, Lee DH, et al. Outcome of endovascular treatment in symptomatic intracranial vascular stenosis. Korean J Radiol 2005;6:1–7

   PubMed
2. Fiorella D, Albuquerque FC, Woo H, et al. Neuroform in-stent stenosis: incidence, natural history, and treatment strategies. Neurosurgery 2006;59:34–42

   CrossRefPubMedWeb of Science
3. SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388–92. Epub 2004 Apr 22.

   Abstract/FREE Full Text
4. Ries T, Buhk JH, Kucinski T, et al. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816–21

   Abstract/FREE Full Text
5. ↵
   Grunwald IQ, Papanagiotou P, Politi M, et al. Endovascular treatment of unruptured intracranial aneurysms: occurrence of thromboembolic events. Neurosurgery 2006;58:612–18

   CrossRefPubMedWeb of Science
6. ↵
   Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597–603

   Abstract/FREE Full Text
7. ↵
   Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823–28

   Abstract/FREE Full Text
8. ↵
   Yan BP, Clark DJ, Ajani AE. Oral antiplatelet therapy and percutaneous coronary intervention. Expert Opin Pharmacother 2005;6:3–12

   CrossRefPubMed
9. ↵
   Cutlip DE. Stent thrombosis: historical perspectives and current trends. J Thromb Thrombolysis 2000;10:89–101

   CrossRefPubMedWeb of Science
10. ↵
    Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 2006;19:439–48

    CrossRefPubMed
11. ↵
    Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246–51

    CrossRefPubMedWeb of Science
12. ↵
    Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007;97:385–93

    PubMedWeb of Science
13. ↵
    von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006;95:910–11

    PubMedWeb of Science
14. ↵
    van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006;4:2516–18. Epub 2006 Aug 28

    CrossRefPubMedWeb of Science
15. ↵
    Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277–84. Epub 2006 Mar 24

    CrossRefPubMedWeb of Science
16. Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the accumetrics Ultegra RPFA-ASA system. Point of Care 2004;3:77–82
17. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295–301

    CrossRefPubMedWeb of Science
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101–08

    CrossRefPubMedWeb of Science
19. ↵
    Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects—the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (suppl 3):234S–64S

    CrossRefPubMedWeb of Science
20. ↵
    Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2006;120:311–21

    CrossRefPubMed
21. ↵
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33

    CrossRefPubMedWeb of Science
22. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20

    CrossRefPubMedWeb of Science
23. ↵
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502

    CrossRefPubMedWeb of Science
24. ↵
    Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392–96

    CrossRefPubMedWeb of Science
25. ↵
    Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol 2006;98:18N–24N

    PubMedWeb of Science
26. ↵
    von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814–19

    Abstract/FREE Full Text
27. ↵
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15. Epub 2007 Nov 4

    CrossRefPubMedWeb of Science
28. ↵
    Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166–286

    FREE Full Text
29. ↵
    Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2006;120:188–92

    CrossRefPubMed
30. ↵
    Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13

    Abstract/FREE Full Text
31. ↵
    Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560–64

    Abstract/FREE Full Text